Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 172 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

 		Follicular Lymphoma (FL) Phase3 Australia
Austria
Canada
Czechia
Hungary
Korea, Republic of
Poland
Romania
Singapore
Slovakia
Spain
Taiwan
United States
View All
 NCT05888493

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

 		Glioblastoma Phase1 France
Spain
Switzerland
United States
View All
 NCT05109728

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

 		Prostatic Neoplasms, Castration-Resistant Phase1 Australia
South Africa 		NCT04597411

Study of Out of Specification for Tisagenlecleucel

 		B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Phase3 Japan NCT04094311

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

 		Multiple Sclerosis Switzerland NCT06156683

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

 		Multiple Sclerosis United States NCT04933552

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

 		Breast Cancer Russian Federation NCT04943497

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

 		C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis Phase3 Argentina
Brazil
China
Czechia
France
Germany
Greece
Israel
Italy
Japan
Netherlands
Spain
Switzerland
Turkey
United Kingdom
United States
View All
 NCT03955445

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

 		Hidradenitis Suppurativa France NCT06444087

Regulatory Post-Marketing Surveillance Study for Brolucizumab

 		Neovascular Age-related Macular Degeneration Korea, Republic of NCT04985487